4-butyl-4-piperidinol | 22093-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-butyl-4-piperidinol
• 英文别名: 4-Butyl-4-hydroxypiperidin；4-Butyl-piperidin-4-ol；4-Butylpiperidin-4-ol
• CAS: 22093-38-5
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: JTOQMUADVWFEKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-butyl-4-piperidinol 、 异氰酸3-苯氧基苯酯 以 1,2-二氯乙烷 为溶剂， 反应 18.0h， 生成 4-butyl-4-hydroxy-N-(3-phenoxyphenyl)-1-piperidinecarboxamide
  参考文献：
  名称：

  REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION

  摘要：

  公开号：

  EP1522314B1
• 作为产物：
  描述：

  1-苄基-4-丁基哌啶-4-醇 在 palladium 10% on activated carbon 甲酸铵 作用下， 以 甲醇 为溶剂， 反应 24.5h， 以100%的产率得到4-butyl-4-piperidinol
  参考文献：
  名称：

  Benzimidazolidinone derivatives as muscarinic agents

  摘要：

  苯并咪唑啉酮衍生物化合物，可增加大脑中乙酰胆碱的信号传导或作用，并且高度选择性的肌碱能激动剂，特别是针对M1和/或M4受体亚型，还公开了包含这些化合物的药物组合物，以及使用这些化合物治疗精神病的方法。

  公开号：

  US20040067931A1

文献信息

• Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity
  申请人：——

  公开号：US20020065292A1

  公开（公告）日：2002-05-30

  Pyrazole compounds represented by the formula: 1 are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-&bgr; mediated diseases and conditions.

  由下式表示的吡唑化合物：1。这些吡唑化合物和含有它们的药物组合物可用于抑制ERAB或HADH2活性，并用于治疗ERAB、HADH2或淀粉样蛋白β介导的疾病和症状。
• Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation
  申请人：Nakade Shinij

  公开号：US20060148844A1

  公开（公告）日：2006-07-06

  A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and/or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.

  一种治疗和/或预防由血管收缩或扩张引起的疾病的药物，包括EDG-5调节剂。由于EDG-5调节剂专门结合EDG-5并显示拮抗或激动作用，因此EDG-5拮抗剂可用于治疗和/或预防由血管收缩引起的疾病，例如蛛网膜下出血或中风后的脑血管痉挛性障碍，心血管痉挛性障碍，高血压，肾脏疾病，心肌梗死，心绞痛，心律失常，促进涉及肝硬化的门静脉血压，涉及肝硬化的静脉曲张等，或EDG-5激动剂可用于治疗和/或预防由血管扩张引起的疾病，例如慢性头痛（如偏头痛，紧张型头痛，混合型头痛或偏头痛性神经痛），痔疮，充血性疾病等。
• Remedies for diseases caused by vascular contraction or dilation
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2508204A2

  公开（公告）日：2012-10-10

  A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and/or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.

  一种治疗和/或预防因血管收缩或血管扩张引起的疾病的药物，包括 EDG-5 调节剂。由于 EDG-5 调节剂特异性结合 EDG-5，并显示出拮抗或激动作用，EDG-5 拮抗剂可用于治疗和/或预防血管收缩引起的疾病，例如蛛网膜下腔出血或中风后的脑血管痉挛性疾病、心血管痉挛性疾病、高血压、肾病、心肌梗塞、心绞痛、心律失常、EDG-5激动剂可用于治疗和/或预防因血管扩张引起的疾病，例如慢性头痛（如偏头痛、紧张型头痛、混合型头痛或偏头痛性神经痛）、痔疮、充血性疾病等。
• PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR MODULATING OR INHIBITING ERAB OR HADH2 ACTIVITY
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：EP1311511A1

  公开（公告）日：2003-05-21
• BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS
  申请人：Kelly Michael Nicholas

  公开号：US20080070948A1

  公开（公告）日：2008-03-20

  Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M 1 and/or M 4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.